Press Releases

Press Releases

May 7, 2024
Procedure revenue growth and strengthened profitability drive solid financial performance Phased launch of BioteRx remains on track Reaffirms 2024 financial guidance, with an acceleration in second half growth IRVING, Texas --(BUSINESS WIRE)--May 7, 2024-- Biote (NASDAQ: BTMD), a leading solutions
April 29, 2024
Company to repurchase all of Founder’s 18.4 million shares at $4.17 per share IRVING, Texas --(BUSINESS WIRE)--Apr. 29, 2024-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and
March 12, 2024
Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enhancing shareholder value with agreement to repurchase 18.4M founders’ shares in addition to a separate $20M share repurchase program Reaffirms 2024 financial guidance,
January 25, 2024
IRVING, Texas --(BUSINESS WIRE)--Jan. 25, 2024-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that its Board of Directors has approved
January 17, 2024
Strategic and accretive transaction enables vertical integration of hormone product manufacturing IRVING, Texas --(BUSINESS WIRE)--Jan. 17, 2024-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized
January 17, 2024
IRVING, Texas --(BUSINESS WIRE)--Jan. 17, 2024-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that management expects 2023 revenue and
Displaying 1 - 10 of 55